Cas:53124-00-8 Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether manufacturer & supplier

Chemical Name:Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether

CAS.NO:53124-00-8

Synonyms:Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether

Molecular Formula:C₄₄H₇₉O₃₅P

Molecular Weight:1199.05086

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether Use and application,Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether technical grade,usp/ep/jp grade.

Related News: You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether manufacturer Coronaviruses are zoonotic, meaning they are transmitted between animals and people. Detailed investigations found that SARS-CoV was transmitted from civet cats to humans and MERS-CoV from dromedary camels to humans. Several known coronaviruses are circulating in animals that have not yet infected humans. Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether supplier You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? Starch, Hydrogen Phosphate, 2-Hydroxypropyl Ether factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?